Sanjal H Desai

16PUBLICATIONS
51CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Haematological tumoursApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Liquid biopsiesPredictive and prognostic markers
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (16)

|Jun 25, 2026
Outcomes of patients with relapsed or refractory classic Hodgkin lymphoma after frontline brentuximab vedotin.

|Jun 24, 2026
Efficacy of post-transplant brentuximab vedotin maintenance by pre-transplant disease status in relapsed/refractory classic Hodgkin lymphoma.

|Mar 27, 2026
Impact of novel therapies on the efficacy of posttransplantation brentuximab vedotin maintenance in Hodgkin lymphoma.

Ayo Samuel Falade, Robert Redd, Sanjal H Desai

|Dec 17, 2025
PD-1-based combinations before autologous transplant are associated with improved outcomes in classical Hodgkin lymphoma.

Sanjal H Desai, Alison J Moskowitz, Reid W Merryman

|Mar 27, 2025
Outcomes in patients with classic Hodgkin lymphoma refractory or intolerant to brentuximab vedotin and anti-PD-1 therapy: a real world analysis from 15 U.S. academic centers.

Timothy J Voorhees, Eric M McLaughlin, Pallawi Torka

|Sep 20, 2023
Overall survival of patients with cHL who progress after autologous stem cell transplant: results in the novel agent era.

Sanjal H Desai, Michael A Spinner, Andrew M Evens

Pageof 3

Frequent Collaborators

5 joint publications

Nuttavut Sumransub

4 joint publications

Yucai Wang

3 joint publications

Gaurav Goyal

3 joint publications

Shin Yeu Ong